Design

At the Human Health Therapeutics Research Centre, our mission to accelerate innovative biologics in Canada starts at the discovery stage. We work with clients and collaborators to design complex early-stage biologics for treating or preventing chronic diseases and emerging infections.

We have expertise in R&D throughout the discovery stage:

  • Target identification
  • Proprietary databases
  • Antibody generation and characterization
  • Humanization
  • Viral vector design and targeting
  • Cell therapy platforms and targeting
  • Vaccine development
  • Analytical development
  • Biophysical characterization
  • Manufacturability assessments

Research areas

Expression systems: Cell line development and protein and viral vector production in animal cells

Antibodies: Antibody generation, antibody characterization and lead optimization using antibodies alone or to target other therapeutics such as chimeric antigen receptor T‑cells (CAR-T cells) or lipid nanoparticles

Vectors: Improvements in the safety and utility of this important class of vectors for use as vaccines or gene therapies

Adjuvants: Production of well-defined, tailor-made, non-toxic and thermostable adjuvants that can be combined with a wide range of antigens

Blood-brain barrier carriers: Development of carriers for delivering therapeutics beyond brain barriers

A man and woman wearing lab coats, safety glasses and gloves stand side by side in a laboratory adjusting a piece of equipment.

Related link(s)

Contact us

Kelley Parato
R&D Director
Biomanufacturing
Telephone: 343-548-6527
Email: Kelley.Parato@nrc-cnrc.gc.ca